Karyopharm Therapeutics Management
Management criteria checks 3/4
Karyopharm Therapeutics' CEO is Richard Paulson, appointed in May 2021, has a tenure of 2.92 years. total yearly compensation is $2.63M, comprised of 28.2% salary and 71.8% bonuses, including company stock and options. directly owns 0.26% of the company’s shares, worth $332.11K. The average tenure of the management team and the board of directors is 2.9 years and 4 years respectively.
Key information
Richard Paulson
Chief executive officer
US$2.6m
Total compensation
| CEO salary percentage | 28.2% |
| CEO tenure | 2.9yrs |
| CEO ownership | 0.3% |
| Management average tenure | 2.9yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 33%
Feb 23
Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)
Feb 05Improved Revenues Required Before Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock's 27% Jump Looks Justified
Apr 17Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Apr 17Karyopharm: Market Is Overlooking Growth
Oct 07Karyopharm Therapeutics Q2 2022 Earnings Preview
Aug 03Karyopharm cancer therapy eltanexor gets FDA fast track status, orphan drug tag in EU
Jul 20Karyopharm: Another 2 Year Wait For Data
May 05Karyopharm: Opportunity To Buy Based On Latest Endometrial Cancer Data And Xpovio Sales Estimates
Feb 19Karyopharm Therapeutics: Unjustified Sell-Off Provides An Opportunity To Reload My Position
Dec 04Karyopharm Therapeutics: After Years Of Waiting I'm Ready To Join The Bulls
Sep 16Analyst Forecasts Just Became More Bearish On Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Aug 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$3m | US$740k | -US$143m |
| Sep 30 2023 | n/a | n/a | -US$140m |
| Jun 30 2023 | n/a | n/a | -US$142m |
| Mar 31 2023 | n/a | n/a | -US$158m |
| Dec 31 2022 | US$7m | US$697k | -US$165m |
| Sep 30 2022 | n/a | n/a | -US$88m |
| Jun 30 2022 | n/a | n/a | -US$104m |
| Mar 31 2022 | n/a | n/a | -US$108m |
| Dec 31 2021 | US$8m | US$468k | -US$124m |
| Sep 30 2021 | n/a | n/a | -US$206m |
| Jun 30 2021 | n/a | n/a | -US$208m |
| Mar 31 2021 | n/a | n/a | -US$201m |
| Dec 31 2020 | US$1m | n/a | -US$196m |
Compensation vs Market: Richard's total compensation ($USD2.63M) is above average for companies of similar size in the US market ($USD667.11K).
Compensation vs Earnings: Richard's compensation has been consistent with company performance over the past year.
CEO
Richard Paulson (56 yo)
2.9yrs
Tenure
US$2,626,288
Compensation
Mr. Richard A. Paulson, M.B.A. has been a Director of Karyopharm Therapeutics Inc. since February 26, 2020 and has been its Chief Executive Officer and President since May 3, 2021. Mr. Paulson has been an...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.9yrs | US$2.63m | 0.26% $ 332.1k | |
| Executive VP | 5.2yrs | US$1.14m | 0.069% $ 88.1k | |
| Executive VP & Chief Commercial Officer | 2.3yrs | US$1.19m | 0.062% $ 78.2k | |
| Executive VP & Chief Development Officer | 2.2yrs | US$1.11m | 0.032% $ 40.5k | |
| Executive VP | 2yrs | US$1.23m | 0.031% $ 39.0k | |
| Clinical Consultant | 14.3yrs | US$208.33k | 0% $ 0 | |
| Co-Founder & Chairman of Scientific Advisory Board | 16.3yrs | US$6.04m | 0.74% $ 934.8k | |
| Vice President of Finance | 5.3yrs | no data | no data | |
| Senior Vice President of Investor Relations | 2.1yrs | no data | no data | |
| Senior VP | 3.3yrs | US$2.06m | 0.037% $ 47.1k | |
| Chief Compliance Officer | 1.5yrs | no data | no data | |
| Vice President of Corporate Communications | no data | no data | no data |
2.9yrs
Average Tenure
50.5yo
Average Age
Experienced Management: KPTI's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.2yrs | US$2.63m | 0.26% $ 332.1k | |
| Clinical Consultant | 13.5yrs | US$208.33k | 0% $ 0 | |
| Co-Founder & Chairman of Scientific Advisory Board | no data | US$6.04m | 0.74% $ 934.8k | |
| Independent Director | 3.4yrs | US$128.33k | 0% $ 0 | |
| Independent Director | 11yrs | US$148.33k | 0% $ 0 | |
| Independent Director | 10.5yrs | US$138.33k | 0.039% $ 49.8k | |
| Lead Independent Director | 11.3yrs | US$173.33k | 0.012% $ 15.0k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.7yrs | US$138.33k | 0% $ 0 | |
| Independent Director | less than a year | US$81.49k | no data | |
| Member of Scientific Advisory Board | 3.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.9yrs | no data | no data |
4.0yrs
Average Tenure
56yo
Average Age
Experienced Board: KPTI's board of directors are considered experienced (4 years average tenure).